Bank of New York Mellon Corp Sells 3,924 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Bank of New York Mellon Corp decreased its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 8.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,083 shares of the company’s stock after selling 3,924 shares during the quarter. Bank of New York Mellon Corp owned 0.08% of Tyra Biosciences worth $382,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Rhumbline Advisers lifted its position in Tyra Biosciences by 7.2% in the 1st quarter. Rhumbline Advisers now owns 28,081 shares of the company’s stock worth $261,000 after buying an additional 1,879 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Tyra Biosciences in the 4th quarter worth approximately $31,000. Wells Fargo & Company MN lifted its position in Tyra Biosciences by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after buying an additional 3,236 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in Tyra Biosciences by 42.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company’s stock worth $110,000 after buying an additional 3,550 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in Tyra Biosciences by 4.4% in the 4th quarter. Wellington Management Group LLP now owns 94,859 shares of the company’s stock worth $1,319,000 after buying an additional 4,034 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Stock Performance

Shares of TYRA stock opened at $10.65 on Tuesday. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The stock has a 50 day moving average price of $10.12 and a two-hundred day moving average price of $10.68. The company has a market capitalization of $565.41 million, a P/E ratio of -6.53 and a beta of 1.08.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. As a group, equities analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Insider Activity

In other news, Director Gilla Kaplan sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $10.31, for a total transaction of $309,300.00. Following the transaction, the director directly owned 59,623 shares of the company’s stock, valued at approximately $614,713.13. The trade was a 33.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 61,392 shares of company stock worth $628,358 over the last 90 days. 15.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on TYRA. Piper Sandler began coverage on Tyra Biosciences in a research report on Wednesday, May 21st. They issued an “overweight” rating and a $33.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Tuesday, July 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $30.83.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.